Orphanet Journal of Rare Diseases (Mar 2023)

GLUT1-DS Italian registry: past, present, and future: a useful tool for rare disorders

  • Costanza Varesio,
  • Valentina De Giorgis,
  • Pierangelo Veggiotti,
  • Nardo Nardocci,
  • Tiziana Granata,
  • Francesca Ragona,
  • Ludovica Pasca,
  • Martina Maria Mensi,
  • Renato Borgatti,
  • Sara Olivotto,
  • Roberto Previtali,
  • Antonella Riva,
  • Maria Margherita Mancardi,
  • Pasquale Striano,
  • Mara Cavallin,
  • Renzo Guerrini,
  • Francesca Felicia Operto,
  • Alice Pizzolato,
  • Ruggero Di Maulo,
  • Fabiola Martino,
  • Andrea Lodi,
  • Carla Marini

DOI
https://doi.org/10.1186/s13023-023-02628-2
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background GLUT1 deficiency syndrome is a rare, genetically determined neurological disorder for which Ketogenic Dietary Treatment represents the gold standard and lifelong treatment. Patient registries are powerful tools providing insights and real-world data on rare diseases. Objective To describe the implementation of a national web-based registry for GLUT1-DS. Methods This is a retrospective and prospective, multicenter, observational registry developed in collaboration with the Italian GLUT1-DS association and based on an innovative, flexible and configurable cloud computing technology platform, structured according to the most rigorous requirements for the management of patient’s sensitive data. The Glut1 Registry collects baseline and follow-up data on the patient’s demographics, history, symptoms, genotype, clinical, and instrumental evaluations and therapies. Results Five Centers in Italy joined the registry, and two more Centers are currently joining. In the first two years of running, data from 67 patients (40 females and 27 males) have been collected. Age at symptom onset was within the first year of life in most (40, 60%) patients. The diagnosis was formulated in infancy in almost half of the cases (34, 51%). Symptoms at onset were mainly paroxysmal (mostly epileptic seizure and paroxysmal ocular movement disorder) or mixed paroxysmal and fixed symptoms (mostly psychomotor delay). Most patients (53, 79%) are currently under Ketogenic dietary treatments. Conclusions We describe the principles behind the design, development, and deployment of the web-based nationwide GLUT1-DS registry. It represents a stepping stone towards a more comprehensive understanding of the disease from onset to adulthood. It also represents a virtuous model from a technical, legal, and organizational point of view, thus representing a possible paradigmatic example for other rare disease registry implementation.

Keywords